Austria Pharmaceuticals & Healthcare Report

Published 13 August 2015

  • 75 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Austria Pharmaceuticals & Healthcare Report

BMI View: While we view the Austrian pharmaceutical and healthcare market as relatively stable and insulated from sudden downgrades, we highlight that certain economic factors pose a risk to public spending in particular. The Austrian government budget deficit was calculated above 2% (2.4%) of GDP in 2014. In our view, this still should limit the ability of the government to increase current spending so as not to see the budget deficit widen further than the 3.0% of GDP limit set by the EU.

Headline Expenditure Projections

  • Pharmaceuticals: EUR4.45bn (USD5.96bn) in 2014 to EUR4.42bn (USD4.86bn) in 2015; -0.6% in local currency terms and -18.4% in US dollar terms. Forecasts unchanged from the previous quarter.

  • Healthcare: EUR35.93bn (USD48.15bn) in 2014 to EUR37.33bn (USD41.06bn) in 2015; +3.9% in local currency terms and -14.7% in US dollar terms. Forecasts unchanged from the previous quarter.

Risk/Reward Index

In our Q415 Pharmaceutical Risk/Reward Index (RRI) we have assigned Austria an RRI score of 64.7, same as in the previous quarter, which means that Austria ranks tenth in the region and scores below the Western European average of 66.9. Notably, Austria holds one of the highest RRI scores globally due to the inherent rewards and low risks that arise from an ageing population, high per capita spending and stable policy environment for drugmakers operating in the country.

Key Trends & Developments

  • In June ViraTherapeutics reported the first closing of a series A financing round, raising EUR3.6mn. The round was co-led by Boehringer Ingelheim Venture Fund and EMBL Ventures and included an investment from Austria Wirtschaftsservice (aws) through its Venture-Capital-Initiative. ViraTherapeutics was created in 2013 as a spin-out from the Medical University of Innsbruck. ViraTherapeutics will use these funds to advance its lead product VSV-GP through preclinical studies prior to clinical Phase Ib testing. VSV-GP is a highly potent oncolytic virus that...

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Austria 2011-2019)
15
Healthcare Market Forecast
15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2011-2019)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2011-2019)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2011-2019)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Austria 2011-2019)
21
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Austria 2011-2019)
23
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Austria 2011-2019)
26
OTC Medicine Market Forecast
26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Austria 2011-2019)
28
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecasts (Austria 2013-2019)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Austria 2013-2019)
30
Key Risks To BMI's Forecast
30
Macroeconomic Forecasts
31
Economic Analysis
31
Table: Economic Activity (Austria 2010-2019)
35
Industry Risk Reward Indices
36
Western Europe Risk/Reward Index - Q4 2015
36
Austria Risk/Reward Index
41
Rewards
41
Risks
41
Market Overview
43
Industry Trends And Developments
46
Epidemiology
46
Healthcare Sector
47
Table: Healthcare Resources (Austria 2009-2014)
49
Table: Healthcare Personnel (Austria 2009-2014)
49
Table: Healthcare Activity (Austria 2009-2014)
50
Research & Development
50
Clinical Trials
51
Regulatory Development
52
Intellectual Property Issues
54
Competitive Landscape
57
Research-Based Industry
57
Pharmaceutical Distribution
58
Table: Members Of ARGE Pharmazeutika, 2011
59
Pharmaceutical Retail
61
Table: Pharmacy Outlets by Type, 2005-2009
62
Table: Pharmacy Outlets by State, 2005-2009
62
Demographic Forecast
63
Table: Population Headline Indicators (Austria 1990-2025)
64
Table: Key Population Ratios (Austria 1990-2025)
64
Table: Urban/Rural Population & Life Expectancy (Austria 1990-2025)
65
Table: Population By Age Group (Austria 1990-2025)
65
Table: Population By Age Group % (Austria 1990-2025)
66
Glossary
68
Methodology
70
Pharmaceutical Expenditure Forecast Model
70
Healthcare Expenditure Forecast Model
70
Notes On Methodology
71
Risk/Reward Index Methodology
72
Index Overview
73
Table: Pharmaceutical Risk/Reward Index Indicators
73
Indicator Weightings
74

The Austria Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Austria Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Austria pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Austria, to test other views - a key input for successful budgeting and strategic business planning in the Austrian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Austrian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Austria.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%